Can-Fite BioPharma (NYSE: CANF) is one of 702 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Can-Fite BioPharma to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.
This table compares Can-Fite BioPharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Can-Fite BioPharma Competitors||-3,753.67%||-191.24%||-32.01%|
Can-Fite BioPharma has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma’s rivals have a beta of 0.41, suggesting that their average share price is 59% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Can-Fite BioPharma and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Can-Fite BioPharma Competitors||7211||19656||37520||1505||2.51|
As a group, “Pharmaceutical preparations” companies have a potential upside of 40.85%. Given Can-Fite BioPharma’s rivals higher possible upside, analysts clearly believe Can-Fite BioPharma has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
1.7% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 43.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Can-Fite BioPharma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Can-Fite BioPharma||$2.03 million||-$9.59 million||-0.57|
|Can-Fite BioPharma Competitors||$1.95 billion||$238.80 million||-1.76|
Can-Fite BioPharma’s rivals have higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Can-Fite BioPharma rivals beat Can-Fite BioPharma on 7 of the 10 factors compared.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.